Compare HUT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | FOLD |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | 511 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2023 | 2006 |
| Metric | HUT | FOLD |
|---|---|---|
| Price | $47.81 | $14.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $56.93 | $27.25 |
| AVG Volume (30 Days) | ★ 3.7M | 2.8M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $235,118,000.00 | N/A |
| Revenue This Year | $161.69 | $20.50 |
| Revenue Next Year | N/A | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $10.11 | $5.66 |
| 52 Week High | $66.07 | $14.46 |
| Indicator | HUT | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 68.84 |
| Support Level | $45.55 | $14.21 |
| Resistance Level | $55.90 | N/A |
| Average True Range (ATR) | 3.61 | 0.02 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 40.85 | 77.78 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.